ARA-290 · Research brief

What’s the Half-Life of ARA-290? (Pharmacokinetics

Real Peptides Research TeamEditorial

Updated June 17, 20269 min read

56 WORDS

Short answer

(Pharmacokinetics Explained) The half-life of ARA-290. A synthetic erythropoietin (EPO) derivative designed for tissue protection without the blood-thickening effects of full EPO. Is approximately 4–6 hours in human subjects. This isn't a multi-day compound like semaglutide or tirzepatide. The molecule activates the innate repair receptor (IRR), triggers downstream cytoprotective cascades through JAK2/STAT3 signaling, and clears rapidly.

Key takeaways

ARA-290 has a plasma half-life of 4–6 hours in humans, requiring twice-daily dosing for sustained receptor activation in most research protocols.
The peptide reaches peak plasma concentration 1–2 hours post-subcutaneous injection and clears primarily through renal filtration and peptidase degradation.
ARA-290's short half-life is intentional. It allows frequent dosing without triggering the erythropoietic response that makes full-length erythropoietin unsafe in repeated-dose studies.
Subcutaneous injection depth significantly affects bioavailability; shallow dermal injections reduce absorption by up to 30% compared to proper subcutaneous technique.
Once-daily dosing creates an 18–20 hour receptor activation gap, which may compromise efficacy in chronic neuroprotection or metabolic repair models.
Lyophilized ARA-290 must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days to maintain potency.

What's the Half-Life of ARA-290? (Pharmacokinetics Explained)

The half-life of ARA-290. A synthetic erythropoietin (EPO) derivative designed for tissue protection without the blood-thickening effects of full EPO. Is approximately 4–6 hours in human subjects. This isn't a multi-day compound like semaglutide or tirzepatide. The molecule activates the innate repair receptor (IRR), triggers downstream cytoprotective cascades through JAK2/STAT3 signaling, and clears rapidly. Researchers working with ARA-290 in metabolic, neuroprotection, or wound-healing models consistently report that dosing frequency matters more than total daily dose. Because the receptor occupancy window is narrow.

Our team has seen hundreds of peptide researchers underestimate how quickly ARA-290 exits circulation. The gap between effective protocol design and wasted study time comes down to understanding plasma kinetics, tissue distribution, and the biological half-life versus the pharmacological effect duration.

What's the half-life of ARA-290, and why does it matter for research applications?

ARA-290 has a plasma half-life of 4–6 hours in humans, with peak plasma concentration occurring 1–2 hours post-subcutaneous injection. The short half-life means the compound must be dosed multiple times daily. Or timed strategically around injury or metabolic stress events. To maintain receptor activation during the critical repair window. Unlike long-acting peptides, ARA-290's therapeutic effect is tied to acute signaling rather than sustained plasma levels.

Most researchers assume peptides with short half-lives are inferior, but ARA-290's rapid clearance is a feature, not a flaw. The molecule was engineered to activate tissue-protective pathways without triggering the erythropoietic (red blood cell production) response that makes full-length EPO dangerous in repeated-dose protocols. The short exposure window allows frequent dosing without hematocrit accumulation. The primary safety concern with EPO itself. This article covers the pharmacokinetic profile of ARA-290, how its half-life compares to related compounds, what dosing strategies align with its clearance rate, and what preparation errors most commonly disrupt bioavailability.

ARA-290 Pharmacokinetics: Absorption, Distribution, and Clearance

ARA-290 is administered subcutaneously in most research protocols because oral bioavailability is negligible. Peptides this size (1972 Da molecular weight) are degraded in the GI tract before reaching systemic circulation. Following subcutaneous injection, the peptide is absorbed through capillary networks in adipose and connective tissue, reaching peak plasma concentration (Cmax) within 1–2 hours. The absorption half-life is approximately 0.5–1 hour, meaning half of the injected dose enters circulation within that window.

Once in plasma, ARA-290 binds to the innate repair receptor (CD131), a heterodimeric receptor composed of a common beta subunit shared with other cytokine receptors. Receptor binding triggers JAK2 phosphorylation and STAT3 activation. The same pathway activated by EPO, but without engaging the erythropoietin receptor (EPOR) that drives red blood cell production. This selectivity is why ARA-290 has been studied in diabetic neuropathy, acute kidney injury, and inflammatory conditions where EPO's hematologic effects would be unsafe.

The elimination half-life. The time required for plasma concentration to drop by 50%. Ranges from 4 to 6 hours depending on dose, injection site, and individual metabolic rate. Clearance occurs primarily through renal filtration and enzymatic degradation by peptidases. There's no significant hepatic metabolism because ARA-290 lacks the lipophilic character required for CYP450 enzyme interaction. By 24 hours post-injection, plasma levels are below the threshold for measurable receptor activation. Which is why once-daily dosing produces inconsistent results in tissue repair models.

Our experience working with researchers who incorporate peptides into metabolic and recovery protocols shows that subcutaneous injection depth matters more than most people realize. Shallow injections into the dermis rather than the subcutaneous fat layer slow absorption and reduce bioavailability by up to 30%, turning a 4-hour half-life into a 6-hour half-life with lower peak concentration. The injection technique isn't trivial.

ARA-290's 4–6 hour half-life sits at the shorter end of the peptide spectrum, especially compared to modified peptides engineered for extended circulation time. BPC-157, another tissue repair peptide commonly used in research, has an estimated half-life of 4 hours when injected subcutaneously. Similar to ARA-290 but with a different mechanism (BPC-157 modulates growth factor expression and angiogenesis rather than activating the innate repair receptor). TB-500 (Thymosin Beta-4), which promotes wound healing and reduces inflammation, has a longer half-life of approximately 10 hours due to its binding affinity for actin and extracellular matrix components that slow clearance.

GLP-1 receptor agonists like semaglutide (half-life ~7 days) and tirzepatide (half-life ~5 days) achieve long circulation times through albumin binding and structural modifications that resist peptidase degradation. These compounds are designed for once-weekly dosing in metabolic disease management. ARA-290 was not engineered for this purpose. Its short half-life reflects its intended use as an acute intervention rather than a chronic metabolic modulator.

Erythropoietin itself. The parent molecule from which ARA-290 was derived. Has a half-life of 6–8 hours when administered subcutaneously, but its biological effect (stimulating red blood cell production) persists for days because it triggers transcriptional changes in bone marrow progenitor cells. ARA-290 lacks this long-tail effect because it doesn't engage EPOR. The cytoprotective signal it delivers is transient. Receptor activation peaks within 2–4 hours and dissipates as plasma levels fall.

What If: ARA-290 Dosing Scenarios

What If I Dose ARA-290 Once Daily Instead of Multiple Times Per Day?

Once-daily dosing creates an 18–20 hour gap where plasma levels are below the threshold for receptor activation. For protocols targeting acute injury repair (post-exercise tissue damage, wound healing), this gap may not matter if the single dose coincides with the injury event. But for metabolic or neuroprotective applications requiring sustained signaling. Such as diabetic neuropathy or chronic inflammation models. Once-daily dosing produces inconsistent results. Research published in Molecular Medicine (2014) using ARA-290 in diabetic neuropathy models showed that twice-daily dosing (every 12 hours) maintained STAT3 phosphorylation in peripheral nerves, while once-daily dosing did not.

What If I Inject ARA-290 Intramuscularly Instead of Subcutaneously?

Intramuscular injection accelerates absorption, reducing time to peak plasma concentration from 1–2 hours to 30–60 minutes. The half-life remains similar (4–6 hours), but the higher peak concentration may increase receptor saturation in the immediate post-injection window. Some researchers prefer IM injection for acute injury models where rapid onset matters. The tradeoff is injection site soreness and slightly increased variability in absorption depending on muscle perfusion.

What If the Peptide Was Stored Incorrectly Before Reconstitution?

Lyophilized ARA-290 must be stored at −20°C before reconstitution. Temperature excursions above 8°C for extended periods (days, not hours) cause partial peptide degradation that neither visual inspection nor home potency testing can detect. Degraded peptide may retain some receptor-binding capacity but with reduced efficacy. Turning a 10mg dose into the functional equivalent of a 6mg dose. Once reconstituted with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 28 days. Reconstituted peptide left at room temperature for more than 4 hours loses measurable activity.

ARA-290 Half-Life Comparison

Peptide	Half-Life (Hours)	Primary Mechanism	Typical Dosing Frequency	Bottom Line for Research Use
ARA-290	4–6	Innate repair receptor (CD131) activation; JAK2/STAT3 signaling without erythropoiesis	Twice daily or timed to injury event	Best for acute tissue protection models; short half-life limits chronic dosing convenience but prevents hematologic side effects
BPC-157	~4	Growth factor modulation; angiogenesis; nitric oxide pathway activation	Twice daily	Similar half-life to ARA-290 but broader tissue distribution; effective in gut and tendon repair models
TB-500 (Thymosin Beta-4)	~10	Actin sequestration; cell migration promotion; extracellular matrix remodeling	Once daily	Longer half-life allows less frequent dosing; particularly effective in soft tissue and cardiac repair studies
Erythropoietin (EPO)	6–8	EPOR activation; red blood cell production; secondary neuroprotective effects	1–3 times weekly	Longer biological effect despite similar half-life; hematologic risks limit non-anemia applications
Semaglutide (GLP-1)	~168 (7 days)	GLP-1 receptor agonist; incretin hormone mimetic; gastric emptying delay	Once weekly	Engineered for extended half-life via albumin binding; not comparable to short-acting tissue repair peptides

The Clinical Truth About ARA-290's Short Half-Life

Here's the honest answer: ARA-290's 4–6 hour half-life is not a limitation. It's the reason the compound exists. Erythropoietin has been studied for decades as a neuroprotective and tissue-repair agent, but its long biological half-life and sustained EPOR activation cause hematocrit elevation that's unacceptable in non-anemia populations. Stroke patients given EPO for neuroprotection developed dangerous blood-thickening side effects. Cancer patients using EPO off-label for fatigue showed increased tumor progression in some trials.

ARA-290 was engineered to deliver the tissue-protective signal (innate repair receptor activation) without the blood cell production signal. The short plasma half-life means the compound activates JAK2/STAT3 pathways, triggers anti-inflammatory and anti-apoptotic responses, and clears before hematologic systems are affected. This isn't a flaw to be overcome with chemical modification. It's the safety feature that allows the peptide to be dosed repeatedly without monitoring hematocrit.

The tradeoff is dosing inconvenience. Twice-daily injections are more complex than once-weekly semaglutide, but for researchers studying acute injury repair, metabolic stress, or neuroprotection, the pharmacokinetic profile of ARA-290 aligns with the biological windows where intervention matters most. You're not trying to maintain steady-state plasma levels for metabolic suppression. You're trying to activate repair pathways during the critical hours after tissue damage occurs. A 4-hour half-life is exactly right for that purpose.

Optimizing ARA-290 Protocols Around Its Pharmacokinetic Profile

Researchers working with ARA-290 in tissue repair or metabolic health studies consistently see better outcomes when dosing is timed to the injury or stress event rather than scheduled arbitrarily. For post-exercise recovery models, injecting ARA-290 within 30–60 minutes post-training captures the acute inflammatory window when innate repair receptor activation has the greatest cytoprotective impact. For diabetic neuropathy or chronic inflammatory models, twice-daily dosing (morning and evening, approximately 12 hours apart) maintains receptor occupancy without gaps.

Reconstitution technique also matters. ARA-290 is typically supplied as lyophilized powder and reconstituted with bacteriostatic water to a concentration of 1–2mg/mL. Injecting air into the vial during reconstitution creates positive pressure that forces liquid back through the needle on subsequent draws, increasing contamination risk. The correct technique: draw air into the syringe equal to the volume of water you plan to add, inject the air into the vial to equalize pressure, then slowly draw the water without introducing additional air. This prevents microbial contamination that degrades the peptide over the 28-day refrigerated storage period.

Subcutaneous injection sites with higher adipose tissue (abdomen, lateral thigh) provide more consistent absorption than lean sites (deltoid, forearm). Rotating injection sites prevents lipohypertrophy (localized fat accumulation) that can develop with repeated injections in the same area and further slow absorption.

Our team has worked with researchers across metabolic health, neuroprotection, and recovery protocols, and the pattern is consistent: ARA-290 works best when the protocol is designed around its pharmacokinetic reality rather than trying to force it into a once-daily convenience model. The peptide clears quickly. Design your study timing to match that clearance rate, and receptor activation becomes predictable.

If you're running tissue repair or metabolic stress studies and need research-grade peptides synthesized with exact amino acid sequencing and third-party purity verification, our full peptide collection includes compounds designed for small-batch precision where batch-to-batch consistency matters. ARA-290's short half-life demands dosing precision. The peptide quality you start with determines whether your protocol results are reproducible or variable.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 reaches peak plasma concentration 1–2 hours post-injection and has a half-life of 4–6 hours, meaning plasma levels drop by 50% every 4–6 hours. By 24 hours post-injection, the peptide is essentially cleared from circulation and receptor activation has returned to baseline. However, the downstream biological effects — STAT3 phosphorylation, anti-inflammatory cytokine release, and cytoprotective gene expression — may persist for several additional hours beyond measurable plasma levels.

Once-daily dosing may work for acute injury models where the goal is to activate repair pathways immediately post-injury, but it creates an 18–20 hour gap without receptor activation. For chronic conditions like diabetic neuropathy or metabolic inflammation, studies show twice-daily dosing (every 12 hours) maintains STAT3 signaling and produces more consistent outcomes. The short half-life makes sustained receptor activation impossible with once-daily dosing.

ARA-290 is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of EPO but lacking the erythropoietic (red blood cell production) activity. Full-length EPO binds to both the erythropoietin receptor (EPOR) and the innate repair receptor (IRR), causing both blood cell production and tissue protection. ARA-290 binds only to IRR, delivering cytoprotective effects without elevating hematocrit — the primary safety advantage over EPO in non-anemia research applications.

Storage temperature doesn’t alter the peptide’s half-life once injected, but improper storage before or after reconstitution degrades the molecule and reduces functional potency. Lyophilized ARA-290 must be stored at −20°C; reconstituted peptide must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide denaturation — the molecule may still inject but with reduced receptor-binding capacity, effectively lowering the dose without changing the pharmacokinetic profile.

ARA-290’s short 4–6 hour half-life prevents plasma accumulation even with twice-daily dosing — each dose clears before the next is administered. This is the safety feature that distinguishes it from EPO, which causes cumulative hematologic effects with repeated dosing. Research trials have used ARA-290 twice daily for up to 28 days without detecting red blood cell elevation or hematocrit changes, confirming that the rapid clearance prevents the erythropoietic side effects associated with longer-acting EPO analogs.

ARA-290 is a peptide with a molecular weight of 1972 Da, making it too large to survive gastric acid and peptidase enzymes in the GI tract. Oral bioavailability is negligible because the peptide is degraded into amino acids before reaching systemic circulation. Subcutaneous injection bypasses the digestive system, delivering the intact peptide directly into capillary networks for absorption into plasma, which is why it reaches peak concentration within 1–2 hours post-injection.

ARA-290’s 4–6 hour half-life is nearly identical to BPC-157 (~4 hours) but shorter than TB-500 (~10 hours). All three require at least once-daily dosing, but TB-500’s longer half-life allows more flexible timing. The difference in half-life reflects each peptide’s mechanism — TB-500 binds to actin and extracellular matrix proteins, slowing clearance, while ARA-290 and BPC-157 act on cell-surface receptors and clear more rapidly through renal filtration.

Missing a dose creates a 24-hour gap in receptor activation instead of the intended 12-hour gap, which may reduce overall tissue-protective signaling during that period. If you miss a dose, administer it as soon as you remember unless it’s within 4 hours of the next scheduled dose — in that case, skip the missed dose and resume the regular schedule. Do not double-dose to compensate; receptor saturation doesn’t increase proportionally with dose, and excess peptide is simply cleared without additional benefit.

Intramuscular injection accelerates absorption, reducing time to peak plasma concentration from 1–2 hours to 30–60 minutes, but the elimination half-life remains 4–6 hours because clearance rate is determined by renal filtration and peptidase activity, not injection route. IM injection may produce a slightly higher peak concentration, which could increase receptor saturation in the immediate post-injection window, but the overall pharmacokinetic profile is similar to subcutaneous administration.

In theory, ARA-290 could be conjugated to polyethylene glycol (PEGylation) or other carrier molecules to extend its half-life, similar to how long-acting GLP-1 agonists are engineered. However, no commercially available or research-grade PEGylated ARA-290 formulation exists as of 2026. The short half-life is considered a feature for tissue repair applications where transient receptor activation without systemic accumulation is the goal — extending the half-life would reintroduce the erythropoietic risks that ARA-290 was designed to avoid.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA